Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 2/20 | 0.38 |
| ▸ | CMA1 | P23946 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7962503 | 0.91 | NPY5R (0.52) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL3791087 | 0.82 | NPC1 (0.47) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7962507 | 0.75 | NPY5R (0.60) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7969172 | 0.75 | NPC1 (0.53) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL10140665 | 0.73 | MEN1 (0.45) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7970001 | 0.72 | GFER (0.56) | MEN1NPC1RAB9AKMT2ANPY5R | |
| SCHEMBL7973223 | 0.72 | NPY5R (0.62) | NPY5RKCNH2ADRA1A | |
| SCHEMBL7973969 | 0.71 | CHEK2 (0.57) | NPY5R | |
| SCHEMBL7976233 | 0.70 | PRSS1 (0.52) | NPY5R | |
| SCHEMBL5786778 | 0.68 | NPY5R (0.85) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | claimed |
| US-RE45173-E1 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8263635-B2 | Inhibitors of CYP 17 | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | MEN1 2911/4885NPC1 701/4885RAB9A 3182/4885 |
| US-20140228394-A1 | INHIBITORS OF CYP 17 | CYP17A1, CYP21A2, CYP4A22 | MEN1 2911/4885NPC1 701/4885RAB9A 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.